An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Developmental and epileptic encephalopathies (DEEs) are complex conditions characterized primarily by seizures associated with neurodevelopmental and motor deficits. Recent evidence supports sigma-1 receptor modulation in both neuroprotection and antiseizure activity, suggesting that sigma-1 receptors may play a role in the pathogenesis of DEEs, and that targeting this receptor has the potential to positively impact both seizures and non-seizure outcomes in these disorders. Recent studies have demonstrated that the antiseizure medication fenfluramine, a serotonin-releasing drug that also acts as a positive modulator of sigma-1 receptors, reduces seizures and improves everyday executive functions (behavior, emotions, cognition) in patients with Dravet syndrome and Lennox-Gastaut syndrome. Here, we review the evidence for sigma-1 activity in reducing seizure frequency and promoting neuroprotection in the context of DEE pathophysiology and clinical presentation, using fenfluramine as a case example. Challenges and opportunities for future research include developing appropriate models for evaluating sigma-1 receptors in these syndromic epileptic conditions with multisystem involvement and complex clinical presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy
Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., & De Jonghe, P. (2001) · The American Journal of Human Genetics · doi:10.1086/320609 · Cited by 1,292 · cited 4×
“The drug fenfluramine, originally described only in terms of serotonin (5-hydroxytryptamine, 5-HT) pharmacology [4–6], recently has demonstrated efficacy in treating DEEs in multiple phase 3 trials [7–10] (Supplemental Table S1 [7–17]).”
BackgroundInfluentialYu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173
Autistic-like behaviour in Scn1a+/− mice and rescue by enhanced GABA-mediated neurotransmission
Han, S., Tai, C., Westenbroek, R. E., Yu, F. H., Cheah, C. S., Potter, G. B., Rubenstein, J. L., Scheuer, T., de la Iglesia, H. O., & Catterall, W. A. (2012) · Nature · doi:10.1038/nature11356 · Cited by 643 · cited 5×
“Scn1a−/− and +/−mice Reduced sodium currents in forebrain GABAergic neurons led to context-dependent spatial memory (rescued by clonazepam, a positive allosteric modulator of GABAA receptors) Han 2017 [33]”
BackgroundInfluentialLagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Self-citationPrognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
Brunklaus, A., Ellis, R., Reavey, E., Forbes, G. H., & Zuberi, S. M. (2012) · Brain · doi:10.1093/brain/aws151 · Cited by 366
Nabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., Stephani, U., Laux, L., Wirrell, E., Knupp, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4113 · Cited by 251
Self-citationDravet syndrome: Characteristics, comorbidities, and caregiver concerns
Villas, N., Meskis, M. A., & Goodliffe, S. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.06.031 · Cited by 184 · cited 1×
“Hyperactivity, attention deficit disorders, and inability to socialize were reported in surveys as behavioral concerns of caregivers [116].”
BackgroundFluvoxamine alleviates ER stress via induction of sigma-1 receptor.
Omi, T., Tanimukai, H., Kanayama, D., Sakagami, Y., Tagami, S., Okochi, M., Morihara, T., Sato, M., Yanagida, K., Kitasyoji, A., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.301 · Cited by 113
Cited by
Knupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J. E., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0829 · Cited by 137
“RESULTS A total of 263 patients (median [range] age, 13 [2-35] years; 146 male patients [56%]) were randomized to the 0.”
BackgroundSelf-citationKnupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2023) · Epilepsia · doi:10.1111/epi.17431 · Cited by 55
Self-citationBishop, K. I., Isquith, P. K., Gioia, G. A., Knupp, K. G., Scheffer, I. E., Nabbout, R., Specchio, N., Sullivan, J., Auvin, S., Helen Cross, J., et al. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108994 · Cited by 43
Self-citationVavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30
Metadata
- Authors
- Martin, P., Reeder, T., Sourbron, J., de Witte, P. A. M., Gammaitoni, A. R., & Galer, B. S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-05
- Volume
- 22
- Issue
- 16
- Pages
- 8416
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3192885085
- Cited by
- 57
- References
- 11
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.